Alpha 2.0
Login Register
» Articles » PMID: 35042991

PROTAC Targeted Protein Degraders: the Past is Prologue

Overview
Journal Nat Rev Drug Discov
Specialty Pharmacology
Date 2022 Jan 19
PMID 35042991
Authors
Miklos Bekes
David R Langley
Craig M Crews
Affiliations
Soon will be listed here.
Abstract

Targeted protein degradation (TPD) is an emerging therapeutic modality with the potential to tackle disease-causing proteins that have historically been highly challenging to target with conventional small molecules. In the 20 years since the concept of a proteolysis-targeting chimera (PROTAC) molecule harnessing the ubiquitin-proteasome system to degrade a target protein was reported, TPD has moved from academia to industry, where numerous companies have disclosed programmes in preclinical and early clinical development. With clinical proof-of-concept for PROTAC molecules against two well-established cancer targets provided in 2020, the field is poised to pursue targets that were previously considered 'undruggable'. In this Review, we summarize the first two decades of PROTAC discovery and assess the current landscape, with a focus on industry activity. We then discuss key areas for the future of TPD, including establishing the target classes for which TPD is most suitable, expanding the use of ubiquitin ligases to enable precision medicine and extending the modality beyond oncology.

Citing Articles

Unraveling the Roles of UBE3A in Neurodevelopment and Neurodegeneration.

Yang X, Huang Y Int J Mol Sci. 2025; 26(5).

PMID: 40076922 PMC: 11900312. DOI: 10.3390/ijms26052304.

Comprehensive investigation of proteoglycan gene expression in breast cancer: Discovery of a unique proteoglycan gene signature linked to the malignant phenotype.

Buraschi S, Pascal G, Liberatore F, Iozzo R Proteoglycan Res. 2025; 3(1).

PMID: 40066261 PMC: 11893098. DOI: 10.1002/pgr2.70014.

A versatile cohesion manipulation system reveals CENP-A dysfunction accelerates female reproductive age-related egg aneuploidy.

Leem J, Lemonnier T, Khutsaidze A, Tian L, Xing X, Bai S bioRxiv. 2025; .

PMID: 40060401 PMC: 11888391. DOI: 10.1101/2025.02.27.640570.

Pharmacokinetics and Pharmacodynamics of KT-474, a Novel Selective Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) Degrader, in Healthy Adults.

Agarwal S, McDonald A, Campbell V, Chen D, Davis J, Rong H Clin Transl Sci. 2025; 18(3):e70181.

PMID: 40055981 PMC: 11889407. DOI: 10.1111/cts.70181.

ALK in cancer: from function to therapeutic targeting.

Voena C, Ambrogio C, Iannelli F, Chiarle R Nat Rev Cancer. 2025; .

PMID: 40055571 DOI: 10.1038/s41568-025-00797-9.

References
1.
Lim S, Khoo R, Peh K, Teo J, Chang S, Ng S . bioPROTACs as versatile modulators of intracellular therapeutic targets including proliferating cell nuclear antigen (PCNA). Proc Natl Acad Sci U S A. 2020; 117(11):5791-5800. PMC: 7084165. DOI: 10.1073/pnas.1920251117. View
2.
Ray S, Murkin A . New Electrophiles and Strategies for Mechanism-Based and Targeted Covalent Inhibitor Design. Biochemistry. 2019; 58(52):5234-5244. DOI: 10.1021/acs.biochem.9b00293. View
3.
He Y, Koch R, Budamagunta V, Zhang P, Zhang X, Khan S . DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas. J Hematol Oncol. 2020; 13(1):95. PMC: 7364785. DOI: 10.1186/s13045-020-00928-9. View
4.
Donovan K, Ferguson F, Bushman J, Eleuteri N, Bhunia D, Ryu S . Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development. Cell. 2020; 183(6):1714-1731.e10. PMC: 10294644. DOI: 10.1016/j.cell.2020.10.038. View
5.
Saerens D, Pellis M, Loris R, Pardon E, Dumoulin M, Matagne A . Identification of a universal VHH framework to graft non-canonical antigen-binding loops of camel single-domain antibodies. J Mol Biol. 2005; 352(3):597-607. DOI: 10.1016/j.jmb.2005.07.038. View